Supplement Contamination Warnings 2026: Yellow Oleander, Tejocote Root, and Undeclared Stimulants

At a Glance

Dietary supplements do not require pre-market FDA approval for safety or efficacy. That regulatory gap, created by the Dietary Supplement Health and Education Act (DSHEA) of 1994, means that contaminated or adulterated products can reach consumers — and in some cases kill them — before authorities can act. In 2026, the FDA’s warning list for supplements adulterated with toxic yellow oleander (Cascabela thevetia) now covers more than 33 products, most sold as tejocote root weight-loss aids. At the same time, broader surveillance of sports and fat-burning supplements continues to uncover undeclared pharmaceutical stimulants including drugs that were withdrawn from the market years ago for cardiovascular harm. This article reviews the clinical toxicology, the current regulatory picture, and the practical steps patients can take to verify what they are actually putting into their bodies.

Yellow Oleander and Tejocote Root: Why These Products Ended Up in the Same Bottle

Tejocote (Crataegus mexicana / Crataegus pubescens) is a Mexican hawthorn that has been used in traditional weight-loss preparations for generations. It is structurally unrelated to yellow oleander and is not acutely toxic in normal doses. Unfortunately, its seeds bear a close physical resemblance to the seeds of Cascabela thevetia — commonly called yellow oleander or be-still tree — a plant of South American and Caribbean origin that contains a family of potent cardiac glycosides: thevetin A, thevetin B, neriifolin, and thevetoxin.

A 2020 review in Cardiology in the Young (Cole JB, Corcoran JN, PMID 33168127) described yellow oleander as a cardiac glycoside source that may be deliberately substituted for genuinely benign weight-loss seeds, including tejocote and candlenuts, when supplies are tight or costs need to be cut. The CDC’s Morbidity and Mortality Weekly Report first drew national attention to the specific tejocote problem in September 2023, when the New Jersey Poison Information and Education System tested ten supplement products sold as tejocote root: nine out of ten contained yellow oleander, and none contained actual tejocote. That finding prompted the FDA’s initial public warning in January 2024, with the warning list expanding steadily through 2025 and reaching more than 33 products by September 2026.

Critically, by 2026 the FDA had also identified products flagged for yellow oleander contamination that were not labelled as containing tejocote at all. This indicates that the contamination is entering the supply chain at the raw material or manufacturing stage, not solely through deliberate mislabeling at the retail level. Any weight-loss supplement containing herbal seed material, particularly those marketed in Spanish or Portuguese and sold through informal online channels, deserves scrutiny regardless of whether tejocote is listed on the label.

Cardiac Glycoside Toxicity: The Clinical Picture

The mechanism of toxicity is identical to digitalis poisoning. Cardiac glycosides inhibit the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular calcium and dramatically slowing conduction through the AV node. In overdose, the result is a spectrum of arrhythmias from sinus bradycardia and first-degree heart block through complete AV dissociation and ventricular fibrillation.

The clinical presentation typically unfolds in two phases:

Phase 1: Gastrointestinal (minutes to hours)

Nausea, vomiting, abdominal cramping, and diarrhoea. These symptoms are the first warning sign and may be dismissed as a stomach upset, particularly if the patient is unaware that their supplement could contain a toxic compound. Many patients do not mention supplement use to their treating physician — a systematic oversight that significantly delays diagnosis.

Phase 2: Cardiovascular and neurological (hours to days)

Sinus bradycardia, prolonged PR interval, ST-segment changes, complete heart block, and in severe cases ventricular fibrillation and cardiac arrest. Neurological effects — including visual disturbances (yellow-green halos, a classic feature of cardiac glycoside toxicity), confusion, delirium, and seizures — can occur in parallel with the cardiac picture.

A 2026 case report (Long SE et al., PMID 42647950, Clinical Practice and Cases in Emergency Medicine) documented this presentation in a patient who had ingested an adulterated supplement, noting the diagnostic challenge when no history of a toxic plant exposure is offered at triage. A second 2026 case (Alnazeer M et al., PMID 41893387, JACC Case Reports) documented a fatal outcome from a weight-loss seed product that required venoarterial extracorporeal membrane oxygenation (VA-ECMO) before the patient succumbed — illustrating that even with maximal haemodynamic support, yellow oleander toxicity at sufficient doses can be unsurvivable.

A 2026 Swiss forensic case study (Theuer T et al., PMID 41883558, Toxicology Reports) used clinical toxicology and forensic botanical analysis to characterise cardiac complications from a herbal supplement of undeclared composition, demonstrating how even products that make no explicit performance claims can harbour compounds with serious cardiovascular potential.

The antidote is digoxin-specific antibody fragments (Fab), sold as Digibind and DigiFab, which bind free cardiac glycoside molecules in the circulation and neutralise their cardiotoxic effects. Prompt administration is life-saving. Delays in diagnosis — common because emergency physicians may not think of supplement adulterants — reduce the window for effective treatment. Any clinician evaluating unexplained bradycardia or AV block should ask specifically about supplement use and consider empiric Fab administration when the history is suggestive.

Undeclared Pharmaceutical Stimulants: The Broader Problem

Yellow oleander is the most acutely lethal supplement adulterant currently in circulation, but it is not the only one of clinical concern. A systematic surveillance programme reported by Cohen PA et al. (PMID 33755516, Clinical Toxicology, 2021) found nine prohibited stimulants across sports and weight-loss supplements, including compounds that have never been evaluated in human safety trials. As of a 2025 review (Corcoran J, PMID 40960841, Clinical Toxicology), cardiovascular toxicity from supplement use continues to generate a steady, preventable stream of emergency department admissions.

The compounds most frequently identified by regulatory surveillance and published case series include:

Sibutramine. A serotonin–norepinephrine reuptake inhibitor withdrawn from the US market in 2010 after the SCOUT trial demonstrated increased risk of non-fatal myocardial infarction and stroke at the therapeutic dose. It continues to appear in weight-loss supplements sold online, particularly those imported through informal channels. Patients with hypertension, coronary artery disease, or arrhythmia are at highest risk.

DMAA (1,3-dimethylamylamine). A synthetic stimulant marketed for years as a natural extract from geranium oil — a claim that was fabricated. Linked to haemorrhagic stroke and cardiac arrest. The FDA banned it as an adulterated food ingredient; it remains available through online marketplaces under various aliases including DMBA, DMHA, and octodrine.

Higenamine. Classified as a beta-2 agonist prohibited under WADA rules. Some supplement brands list it as Nandina domestica extract, allowing a degree of label compliance while the pharmacologically active compound remains present. Associated with tachycardia and hypertension.

Synephrine analogues (oxilofrine, octopamine). Structurally related to adrenaline. Raise blood pressure and heart rate and have been associated with acute coronary syndromes in young, otherwise healthy adults — including in sports supplements sold over the counter.

DNP (2,4-dinitrophenol). An industrial chemical that uncouples oxidative phosphorylation, generating heat from stored energy. Causes uncontrolled hyperthermia, profuse sweating, tachycardia, and, at sufficient doses, is directly lethal. Deaths have been reported in the UK, US, Australia, and continental Europe every year despite explicit bans. It is sold online as a weight-loss product.

Who Is at Greatest Risk?

The highest-risk consumer profile is a person who:

1. Purchases supplements online from non-established vendors — including third-party marketplace sellers on Amazon, eBay, TikTok Shop, or social media storefronts operating outside standard retail oversight.
2. Uses weight-loss, fat-burning, or body-composition products — the category with the highest contamination rates in regulatory surveys, particularly products marketed in Spanish or Portuguese and aimed at Hispanic and Latino communities through the tejocote narrative.
3. Has pre-existing cardiovascular disease — including subclinical hypertension or arrhythmia, where the threshold for a toxic event is substantially lower.
4. Takes prescription medications that interact with stimulants or cardiac glycosides — including digoxin (additive cardiac glycoside load), MAOIs, beta-blockers, antihypertensives, and antidepressants that affect monoamine reuptake. For a detailed treatment of how supplements interact with prescription medications, see the separate article on berberine drug interactions, which applies the same framework to CYP3A4 inhibitors and covers the interaction logic that applies broadly across supplement categories.
5. Is not supervised by a physician or does not disclose supplement use — an estimated 50–80% of patients in primary care do not inform their treating physician of supplement use, depriving the team of critical information when a complication arises.
6. Is a child in a household where adulterated products are present. The 2023 CDC incident that triggered the original FDA warning involved a toddler who was accidentally exposed to a parent’s tejocote supplement.

Practical Guidance: How to Verify What You Are Taking

No patient should assume that a natural-sounding label, a celebrity endorsement, or a “third-party tested” claim on the label itself constitutes proof of product safety. The following steps are verifiable:

Check the FDA’s current warning list. The FDA maintains a public list of products flagged for yellow oleander adulteration on its website. It is updated as new products are identified. A product not currently on the list is not automatically safe, but a product that is on it should be stopped immediately.

Require a certificate of analysis (COA) from an independent accredited laboratory. A reputable manufacturer can produce a current-year COA from a laboratory accredited under ISO/IEC 17025. The COA should include botanical identity confirmation (DNA barcoding is now standard for plant-based products) and a pharmaceutical adulterant screen covering sibutramine, DMAA, higenamine, synephrine analogues, and their known analogues. If a vendor cannot or will not produce one, that is sufficient reason not to buy the product.

Use recognised third-party certifications. NSF International (NSF/ANSI 173), USP Verified, and Informed Sport/Informed Choice certify products after independent lot testing. These marks are more meaningful than a manufacturer’s in-house “tested” claim, though none covers every adulterant or every production lot. When selecting any longevity or integrative supplement, the approach used in evaluating an integrative clinic — asking for evidence, not accepting marketing language — applies equally to individual products.

Tell your physician. If you are taking any supplement — particularly one for weight management, athletic performance, or energy — disclose it at every clinical encounter. Cardiac glycoside poisoning can mimic multiple medical conditions; the treating physician cannot test for what they do not know to look for. This applies with particular force when you are on prescription medications: even supplements that are not adulterated can affect drug metabolism. Independently of the contamination problem, lab monitoring supports safe supplement use; the functional medicine labs framework offers a practical starting point for the kind of baseline and interval testing that catches problems early.

What to Do If You Suspect Contamination

If you are taking a product on the FDA’s yellow oleander warning list, or experience unexplained nausea, vomiting, heart palpitations, bradycardia, or visual disturbances after starting a new supplement:

1. Stop the product immediately.
2. Call emergency services (112 in Germany, 911 in the US, 999 in the UK) or go directly to the nearest emergency department. This is a potential cardiac emergency.
3. Bring the product container and any available documentation — order confirmation, label photographs, lot number — to the hospital.
4. Inform the emergency team that the product may contain cardiac glycosides. This will prompt ECG monitoring, digoxin-level testing, and consideration of digoxin-specific Fab fragments.

Patients in acute danger from any cause should contact emergency services immediately. If you are in a mental health crisis or experiencing suicidal thoughts, call your local emergency line or crisis number right away.

Related Articles

• Berberine Drug Interactions: What Every Patient on Berberine Needs to Know
• NAD⁺ IV Therapy: Contraindications and Patient Safety
• How to Evaluate an Integrative Clinic: A Patient’s Checklist
• Functional Medicine Lab Testing: What to Request and Why
• CoQ10 for Heart Health: What the Clinical Evidence Actually Shows